Physician profile
Stacey W Steeves
NPI 1457562233
$548,023.16
in general payments reported to CMS, 2019-2025
47 companies · $17K in 2025
The $17K reported for 2025 was more than what 92% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $122K · 2020: $137K · 2021: $120K · 2022: $97K · 2023: $28K · 2024: $26K · 2025: $17K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $55K · Consulting Fee: $7,600 · Food and Beverage: $5,547 · Travel and Lodging: $3,405 · Education: $72.50.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $55,021.25 |
| Consulting Fee | $7,600.00 |
| Food and Beverage | $5,547.22 |
| Travel and Lodging | $3,404.78 |
| Education | $72.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $138,497.45 | 2019-2025 | Reyvow, Emgality, Kisunla |
| Abbvie INC. | $131,215.19 | 2021-2025 | Qulipta, Ubrelvy, Botox |
| Amgen INC. | $92,196.67 | 2019-2025 | Uplizna, Aimovig |
| Teva Pharmaceuticals USA, INC. | $60,254.30 | 2019-2025 | Ajovy, Austedo Xr, Austedo Xr |
| Allergan, INC. | $59,355.18 | 2019-2021 | |
| Impel Pharmaceuticals INC. | $17,570.27 | 2022-2023 | Trudhesa |
| Biohaven Pharmaceuticals, INC. | $16,938.46 | 2020-2021 | |
| Lundbeck LLC | $14,503.22 | 2020-2025 | Vyepti, Rexulti |
| Biohaven Pharmaceutical Holding Company Ltd. | $10,018.00 | 2022 | |
| Emd Serono, INC. | $2,135.94 | 2019-2025 | Mavenclad, Mavenclad |
| Celgene Corporation | $901.63 | 2019-2025 | Zeposia |
| Genzyme Corporation | $649.57 | 2019-2025 | |
| Tg Therapeutics, INC. | $399.44 | 2023-2025 | |
| Novartis Pharmaceuticals Corporation | $379.86 | 2019-2024 | |
| Alexion Pharmaceuticals, INC. | $356.20 | 2019-2024 | Ultomiris |
Show all 47 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biogen, INC. | $354.05 | 2019-2025 | Vumerity, Tysabri |
| Genentech USA, INC. | $205.66 | 2021-2025 | Ocrevus Zunovo, Ocrevus, Enspryng |
| Acorda Therapeutics, INC | $199.20 | 2019-2024 | Ampyra, Inbrija |
| Amneal Pharmaceuticals LLC | $171.07 | 2019-2024 | Rytary, Crexont |
| Upsher-Smith Laboratories LLC | $165.49 | 2019-2022 | |
| Supernus Pharmaceuticals, INC. | $160.93 | 2019-2020 | |
| Pfizer INC. | $134.85 | 2023-2025 | |
| Banner Life Sciences, LLC | $126.31 | 2021-2024 | |
| Eisai INC. | $123.77 | 2024 | |
| Csl Behring | $93.70 | 2024-2025 | Hizentra |
| E.R. Squibb & Sons, L.L.C. | $90.67 | 2021-2022 | |
| Greenwich Biosciences, INC. | $86.17 | 2019 | |
| Ucb, INC. | $78.15 | 2019-2025 | Rystiggo |
| Neurocrine Biosciences, INC. | $76.83 | 2019-2024 | Ingrezza |
| Avanir Pharmaceuticals, INC. | $74.74 | 2019-2021 | |
| Ani Pharmaceuticals, INC. | $71.51 | 2022-2025 | Purified Cortrophin Gel |
| Genentech, INC. | $51.85 | 2025 | Ocrevus, Ocrevus Zunovo |
| Acadia Pharmaceuticals INC | $46.27 | 2024-2025 | Nuplazid, Daybue |
| Currax Pharmaceuticals LLC | $45.48 | 2020-2021 | |
| Merz Pharmaceuticals, LLC | $34.12 | 2024 | Xeomin |
| Axsome Therapeutics, INC. | $32.26 | 2025 | Symbravo |
| Ipsen Biopharmaceuticals, INC | $30.97 | 2019 | |
| Mallinckrodt Hospital Products INC. | $29.08 | 2025 | Acthar |
| Cycle Pharmaceuticals INC | $27.00 | 2025 | Bafiertam, Tascenso Odt |
| Janssen Pharmaceuticals, INC | $23.87 | 2021 | |
| Argenx US, INC. | $22.82 | 2024 | Vyvgart Hytrulo, Vyvgart |
| Otsuka America Pharmaceutical, INC. | $20.50 | 2024 | Nuedexta |
| Sunovion Pharmaceuticals INC. | $17.64 | 2019 | |
| Sk Life Science, INC. | $14.69 | 2024 | |
| Neurelis, INC. | $14.30 | 2025 | Valtoco |
| Zyla Life Sciences, INC. | $14.17 | 2019 | |
| Horizon Therapeutics Plc | $13.66 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stacey Steeves listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.